Aurinia Pharmaceuticals AUPH Lessee Operating Lease Liability Payments Due

Lessee Operating Lease Liability Payments Due at other companies

Agios PharmaceuticalsAGIO

——

Mirum Pharmaceuticals, Inc.MIRM

——

BridgeBio PharmaBBIO

——

AbbottABT

——

Other financials

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation

See full

Market cap$2.3B+78.5%

Enterprise value$2.34B+78.3%

P/E7.7×-24.6×

P/S7.7×+2.5×

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's lessee operating lease liability payments due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's lessee operating lease liability payments due?: Aurinia Pharmaceuticals (AUPH) reported lessee operating lease liability payments due of $4.3M in Q1 2026.
How has Aurinia Pharmaceuticals's lessee operating lease liability payments due changed year-over-year?: Aurinia Pharmaceuticals's lessee operating lease liability payments due decreased by 44.5% year-over-year, from $7.75M to $4.3M.